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ABSTRACT
Introduction Cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy (CRS- HIPEC) has become 
standard of care for patients with peritoneal metastases 
of colorectal origin with a low/moderate abdominal 
disease load. In case of a peritoneal cancer index (PCI) 
score >20, CRS- HIPEC is not considered to be beneficial. 
Patients with a PCI >20 are currently offered palliative 
systemic chemotherapy. Previous studies have shown that 
systemic chemotherapy is less effective against peritoneal 
metastases than it is against haematogenous spread 
of colorectal cancer. It is suggested that patients with 
peritoneal metastases may benefit from the addition of 
intraperitoneal chemotherapy to systemic chemotherapy. 
Aim of this study is to establish the maximum tolerated 
dose of intraperitoneal irinotecan, added to standard of 
care systemic therapy for colorectal cancer. Secondary 
endpoints are to determine the safety and feasibility of this 
treatment and to establish the pharmacokinetic profile of 
intraperitoneally administered irinotecan.
Methods and analysis This phase I, ‘3+3’ dose- 
escalation, study is performed in two Dutch tertiary referral 
centres. The study population consists of adult patients 
with extensive peritoneal metastases of colorectal origin 
who have a good performance status and no extra- 
abdominal metastases. According to standard work- up for 
CRS- HIPEC, patients will undergo a diagnostic laparoscopy 
to score the PCI. In case of a PCI >20, a peritoneal access 
port will be placed in the abdomen of the patient. Through 
this port we will administer intraperitoneal irinotecan, in 
combination with standard systemic treatment consisting 
of 5- fluorouracil/leucovorin with oxaliplatin and the 
targeted agent bevacizumab. Therapy consists of a 
maximum of 12 cycles 2- weekly.
Ethics and dissemination This study protocol is 
approved by a research medical ethics committee 
(Rotterdam, Netherlands) and the Dutch Competent 
Authority (CCMO, The Hague, Netherlands). The results 
of this trial will be submitted for publication in a peer- 
reviewed scientific journal.
Strengths and limitations of this study
 ► The INTERACT study may be the first step towards 
a more effective, life prolonging and possible even 
curative treatment for patients with extensive peri-
toneal metastases of colorectal cancer who are not 
eligible for cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy.
 ► In patients with peritoneal metastases of gastric and 
ovarian cancer, the addition of concomitant intra-
peritoneal chemotherapy to systemic chemotherapy 
showed promising results.
 ► This study will provide essential information, the 
maximum tolerated dose (MTD), safety and feasibil-
ity of treatment with intraperitoneal irinotecan, for 
the conduction of further clinical research.
 ► Establishing the pharmacokinetic profile of intraperi-
toneally administrated irinotecan is an essential part 
of this study, because this will provide crucial infor-
mation for further research on the behaviour and 
use of intraperitoneally administrated irinotecan.
 ► In this phase I dose- escalation trial the added value 
of intraperitoneal chemotherapy to systemic chemo-
therapy on overall survival cannot be determined, 
when the MTD is determined, larger phase II and 
III clinical trials will be conducted to determine the 
effect on survival.
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InTRoduCTIon
Colorectal cancer is the third most common cancer in the 
Netherlands. About 15% of patients will develop perito-
neal metastases at some stage of disease. Approximately 
5% already has peritoneal metastases at time of diagnosis 
of the primary tumour (synchronous metastases), while 
the other 10% develop peritoneal metastases during 
follow- up after treatment of the primary tumour (meta-
chronous metastases).
Cytoreductive surgery and hyperthermic intraperito-
neal chemotherapy (CRS- HIPEC) is the only curative 
treatment option for patients with peritoneal metastases 
of colorectal origin and has become standard of care for 
patients with a low to moderate abdominal disease load.1–4 
The extent of disease is evaluated using the peritoneal 
cancer index (PCI) which ranges from 0 (no disease) to 
39 (extensive disease in all 13 regions of the abdomen); a 
PCI above 20 is considered to be too high for CRS- HIPEC 
to be beneficial.4–6
Unfortunately, most patients with peritoneal metastasis 
are not eligible for CRS- HIPEC.7 8 In the Netherlands, 
approximately 23% of all patients diagnosed with peri-
toneal metastasis from colorectal cancer undergo CRS- 
HIPEC, 56% is treated with systemic therapy.8 Current 
radiological imaging techniques are valuable in the detec-
tion of distant metastasis but underestimate the extend 
of peritoneal disease.9–11 To prevent unnecessary open- 
close procedures/laparotomies in patients with a PCI 
>20, a diagnostic laparoscopy (DLS) is recommended 
during preoperative work- up for CRS- HIPEC.12 13 DLS 
can prevent up to 40% of open- close procedures.13 
Patients with a PCI >20 or irresectable disease during DLS 
or open- close procedures are currently offered treatment 
with palliative systemic chemotherapy or best supportive 
care.
Previous studies have shown that patients with perito-
neal metastases of colorectal origin have worse survival 
rates than patients with colorectal cancer with non- 
peritoneal metastases.14–17 This suggests that systemic 
therapy is less effective against peritoneal metastases 
than it is against the haematogenous metastases. Perito-
neal metastases might also be a sign of poor biological 
behaviour of the primary tumour. Moreover, patients 
are often in a poor condition and not- eligible for treat-
ment with chemotherapy. As a result of all the above, the 
prognosis of patients with extensive peritoneal metas-
tases is poor. Median survival of patients not treated with 
systemic chemotherapy is 3–5 months.18 19 In patients 
treated with systemic chemotherapy the median survival 
is 9–15 months.14 18 Since the survival of patients with 
extensive intraperitoneal disease who are not eligible for 
CRS- HIPEC is poor, even with maximal treatment with 
systemic chemotherapy, the question raised how the treat-
ment of these patients can be improved.
It has been suggested that intraperitoneal chemo-
therapy may be more effective for the treatment of peri-
toneal metastases than systemic chemotherapy.20–22 In 
patients with peritoneal metastases of gastric and ovarian 
cancer, the addition of concomitant intraperitoneal 
chemotherapy to systemic chemotherapy showed prom-
ising results.21–28 It is our hypothesis that adding intra-
peritoneal chemotherapy will also improve outcomes 
for patients with peritoneal metastases of colorectal 
origin. However, before initiating phase II and III studies 
that assess the potential added value of intraperitoneal 
chemotherapy to systemic chemotherapy, the phase I 
dose- finding study such as described in this protocol 
needs to be conducted. Aim of this classic phase I ‘3+3’ 
dose escalation study is to establish the maximum toler-
ated dose (MTD) for the intraperitoneal chemotherapy 
in combination with standard of care systemic chemo-
therapy. Currently, the standard first line systemic therapy 
for the treatment of metastatic colorectal cancer in the 
Netherlands is a combination of a fluoropyrimidine 
(5- fluorouracil/leucovorin ((5- FU/LV) or capecitabine) 
with oxaliplatin (FOLFOX/CAPOX) and the target agent 
bevacizumab.29
In this study it was chosen to administrate irinotecan 
intraperitoneally. Irinotecan is an effective anti- cancer 
drug for multiple malignancies, including colorectal 
cancer.30 An additional argument for irinotecan as 
intraperitoneal agent is that it will not affect the plasma 
area under the curve of the agents 5- FU and oxaliplatin 
that are administered intravenously. Irinotecan’s main 
cytotoxicity is attributed to its metabolite SN-38, which 
is 100–1000- fold more cytotoxic than irinotecan.31 32 
Conversion to SN-38 takes place in the liver by carbox-
ylesterases, but previous studies showed this conversion 
also takes place in the intraperitoneal space.31–34 Admin-
istration of intraperitoneal irinotecan was proven to 
be safe in patients with peritoneal metastases of gastric 
origin.23 35 36 Simultaneous systemic administration of 
FOLFOX and irinotecan (FOLFIRINOX/FOLFOXFIRI) 
also has been studied extensively and is considered safe 
and effective and is currently standard of care in patients 
with pancreatic cancer.29 37 38 We therefore expect that 
that the combination of systemic FOLFOX and intraperi-
toneal irinotecan is feasible.
METhodS And AnAlySIS
This protocol summary follows the Standard Protocol 
Items: Recommendations for Interventional Trials 
(SPIRIT) Statement.39
Study design
The INTERACT trial is a multicentre, single- arm, open- 
label, phase I dose finding study that follows the classic 
‘3+3’ dose- escalation design.40 41 Explanation of the ‘3+3’ 
design plus the defined dose levels ranging from 50 mg 
to 400 mg irinotecan are shown in figure 1. All patients 
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Figure 1 3+3 dose escalation study design of the INTERACT trial. MTD, maximum tolerated dose.
included in this trial will receive concomitant intraperito-
neal and systemic chemotherapy.
Study setting
This study is conducted in two tertiary referral hospitals 
for the treatment of peritoneal metastases in the Neth-
erlands; the Erasmus MC Cancer Institute in Rotterdam 
and the Catharina Cancer Institute in Eindhoven.
Primary objective
The primary objective of this study is to establish the 
MTD and recommended phase II dose (RP2D) of intra-
peritoneal irinotecan added to systemic FOLFOX and 
bevacizumab.
Maximum tolerated dose/recommended phase II dose
The MTD is defined as the highest dose that is given, 
leading to ≤33% dose limiting toxicity (DLT). The MTD 
will be considered the RP2D (figure 1). If 2/3 patients 
experience DLT at dose level 1, a 50% dose- de- escalation 
to 25 mg irinotecan i.p. may be performed. If the MTD 
is not reached, the RP2D will be the dose given at dose 
level 5.
Dose limiting toxicity
Toxicity will be graded using the Common Terminology 
Criteria for Adverse Events (CTCAE) V.4.03. A DLT is 
considered possibly, probably or definitely related to the 
addition of intraperitoneally administered irinotecan to 
FOLFOX. DLT is defined in the following subsections.
Haematology
 ► Absolute neutrophilic count (ANC) <0.5×109/L 
(grade 4) lasting longer than 7 days.
 ► Febrile neutropenia (ANC <1.0×109/L, fever >38.5°C) 
(grade three or 4).
 ► Platelets <25×109/L (grade 4).
Non-haematology
Grade 3 or 4 non- haematological adverse events (AEs) 
except nausea/vomiting, diarrhoea or fatigue for which 
the following DLT definitions will apply:
 ► Nausea ≥grade 3 despite optimal anti- emetic use.
 ► Diarrhoea ≥grade 3 despite optimal loperamide use.
 ► Grade 3 fatigue lasting longer than 7 days.
Other
Delay of the next cycle by more than 2 weeks.
Secondary objectives
Secondary objectives are to explore the safety and feasi-
bility of this treatment and to establish the pharmacoki-
netic profile of intraperitoneally administered irinotecan. 
During the study we will also systematically collect, process 
and store ascites for translational research purposes, 
including the genetic analysis of circulating tumour cells 
(CTCs) and the derivation of organoid cultures as an ex 
vivo platform for studying drug response and resistance 
in individual patients.
Study population
The study population consists of adult patients diag-
nosed with inoperable peritoneal metastases of colorectal 
origin. Potentially eligible patients will be referred by 
their local clinician or through self- referral to a medical 
specialist. All potentially eligible patients will be checked 
at the outpatient clinic by a member of the study team, 
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Figure 2 Flowchart INTERACT- trial. CRS- HIPEC, 
cytoreductive surgery and hyperthermic intraperitoneal 
chemotherapy; CTx, chemotherapy; DLS, diagnostic 
laparoscopy; IP, intraperitoneal; IV, intravenous; PCI, 
peritoneal cancer index.
who will thoroughly inform the patient about trial and 
determine the eligibility of the potential participant.
In order to be eligible to participate in this study, 
patients must meet the following inclusion criteria:
 ► Patients with a histologically confirmed diagnosis of 
colorectal cancer.
 ► Radiologically or clinically confirmed diagnosis of 
peritoneal metastases.
 ► Unknown PCI for which a DLS is planned in the 
work- up for CRS- HIPEC or a known PCI >20 evalu-
ated by laparoscopy or laparotomy before inclusion 
in this trial.
 ► WHO- Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1.
 ► Life expectancy of at least 3 months.
 ► Normal organ function and adequate bone marrow 
reserve, as assessed by the following laboratory 
requirements:
 – Absolute neutrophil count >1.5×109/L.
 – Platelet count >100×109/L.
 – Hb >6.0 mmol/L.
 – Bilirubin <1.5× upper limit of normal (ULN).
 – Serum aspartate transaminase (AST) and alanine 
transaminase (ALT) <2.5× ULN.
 – GFR >45 mL/min and Creatinine clearance <2× 
ULN.
 ► Age ≥18 years old.
 ► Written informed consent according to the Interna-
tional Council for Harmonisation- good clinical prac-
tice and national/local regulations.
 ► Ability to return to the Erasmus MC Cancer Institute/
Catharina Cancer Institute for adequate follow- up.
A potential subject who meets any of the following 
exclusion criteria will be excluded from participation in 
this study:
 ► Extra- abdominal disease, established by CT scan of 
thorax- abdomen and/or positron emission tomog-
raphy scan. Imaging not older than 1 month at time 
of surgery.
 ► Prior cytoreductive surgery.
 ► Prior treatment with chemotherapy for (metastatic) 
colorectal cancer within the last 6 months.
 ► Serious concomitant disease or active/chronic infec-
tions, including HIV and viral hepatitis.
 ► Homozygous UGT1A1*28 genotype or homozygous 
or (compound) heterozygous DPYD genotype (tested 
for *2A, *13, 2846A>T and 1236G>A).
 ► Current use of strong CYP3A4- inhibitors or inducers. 
If patients use this CYP3A4- modulating medication, it 
is allowed to stop it within 14 days of start of treatment.
 ► Concomitant participation in another competing 
clinical study or absence of assurance of compliance 
with the protocol.
 ► An organic brain syndrome or other significant psychi-
atric abnormality which would comprise the ability to 
give informed consent, and preclude participation in 
the full protocol and follow- up.
 ► Pregnant or lactating women.
Patient timelines and additional procedures
Figure 2 describes a flowchart of the study. A more 
detailed description of (additional) study procedures are 
shown in figure 3 and table 1.
Screening
After informed consent is acquired by a member of the 
study team, a screening will be performed. Screening 
procedures include laboratory testing (including geno-
type testing), an ECG, and a (new) CT- scan of the thorax 
and abdomen (only when the previous imaging is older 
than 1 month at time of surgery). When patients comply 
to all previously described eligibility criteria, they will be 
scheduled for a DLS. All patients require formal anaes-
thetic assessment prior to surgery.
Surgical procedures
All patients will be operated under general anaesthesia, 
according to local hospital procedures. During the DLS 
the extent of peritoneal disease is scored using the PCI- 
score. In case of a PCI >20, a peritoneal access port will 
be placed on the fascia of the right lower rib- cage. The 
catheter is inserted in the abdomen and the tip will be 
positioned in the pouch of Douglas. Laparoscopic place-
ment is considered the golden standard.42 After surgery, 
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Figure 3 Study procedures. CRS- HIPEC, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; CT- Th/Abd, 
CT tomography thorax and abdomen; CTx, Chemotherapy; DLS, diagnostic laparoscopy; IP, intraperitoneal; IV, intravenous; 
PCI, peritoneal cancer index.
patients may leave the hospital on the same day, with 
careful instructions. Postoperative patients are seen in 
the outpatient department by both the surgeon and the 
medical oncologist. The start date of the first treatment 
cycle of chemotherapy will be determined according to 
patients’ individual recovery after the DLS.
Chemotherapy
Patients will receive intraperitoneal irinotecan (according 
to dose- level, see figure 1) dissolved in one litre sodium 
chloride solution 0.9% 37°C through the peritoneal 
access port. The intraperitoneal chemotherapy will be 
administered by a member of the study team at the start 
of the first day of the cycle of systemic chemotherapy, this 
will take 1.5 hour. The treatment with intraperitoneal 
chemotherapy will take place in the medical oncology 
department, since simultaneous administration of 
systemic chemotherapy (FOLFOX and bevacizumab) will 
be performed according to the local standard protocol 
including premedication and anti- emetics. If any surgical 
problems occur during the treatment, a surgical oncolo-
gist is always available for consultation or clinical assess-
ment of the patient.
The combination therapy of intraperitoneal and 
systemic chemotherapy will be continued until disease 
progression, unacceptable toxicity, irreversible compli-
cations related to the peritoneal access port, or patients 
wish to discontinue the treatment for a maximum of 12 
cycles.
Follow-up
Patients are assessed weekly during the first two cycles. 
Further follow- up and response evaluation of the combi-
nation therapy is according to the local standard protocol 
for patients receiving systemic FOLFOX and bevaci-
zumab. To evaluate the response of the combination 
therapy a CT- scan will be obtained after every fourth cycle 
of chemotherapy. If the CT- scan shows stable disease or 
a partial response, treatment with chemotherapy will be 
continued.
Problems related to the peritoneal access port
In case complications related to the peritoneal port occur 
the treating physician should be informed, discuss the 
problem with the study team, and handle in the patient’s 
best medical interest. Previous studies that adminis-
trated intraperitoneal chemotherapy reported problems 
like catheter obstruction, port dysfunction, infection, 
and abdominal pain during administration of chemo-
therapy.43–45 In certain cases the peritoneal port might 
have to be replaced to continue treatment, in others cases 
patients might have to discontinue study participation. 
Pain medication (oral or intravenous) could be admin-
istrated to relieve discomfort during administration of 
chemotherapy.
Removal of the peritoneal access port
After completion of the cycles of chemotherapy, or after 
discontinuation of the trial, the peritoneal access port will 
be removed by the surgeon. Removal of the access port 
will be performed under local anaesthesia, or if there is 
any reason why this is not deemed feasible, the peritoneal 
access port can also be removed under general anaes-
thesia with a laparoscopy.
Withdrawal of individual subjects
Subjects can discontinue participation in the study at any 
time for any reason, without any consequences. The inves-
tigator can decide to withdraw a subject from the study 
for urgent medical reasons. In case a patient or the study 
coordinator decides to withdraw from further participa-
tion, all efforts will be made to complete and report the 
observations as thoroughly as possible.
The investigators also have the right to withdraw 
patients from the study if one of more of the following 
events occur:
 ► Significant protocol violation or non- compliance on 
the part of the patient or investigator.
 ► Refusal of the patient to continue treatment or 
observations.
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 ► Any change in the condition of the patient that justi-
fies discontinuation of treatment.
 ► Progressive disease during response evaluation 
(CT- scan).
 ► Decision by the study coordinator that termination is 
in the patient’s best medical interest.
 ► Unrelated medical illness or complication.
Sample size calculation and statistical analysis
Because of the nature of this study (dose- escalation 
study), the number of patients to be included is variable 
pending on data obtained during different dose levels 
(see figure 1 for dose- escalation design and for dose- 
levels). A minimum of three patients will be entered on 
each dose- level and a maximum of six. The total number 
of predefined dose levels is five. No intra- patient dose- 
escalation will be applied. When the MTD is established, 
a total of nine patients will be treated with this dose. This 
comes to a sample size calculation of a minimum of four 
patients (in case 2/3 patients experience DLT at dose 
level 1, a dose a dose- de- escalation will be performed with 
again a minimum of two patients) and a maximum of 33 
patients.
The statistical analyses and data summaries will be 
performed using SPSS version 25.0.0.1. Other tools 
may be used for exploratory summaries and graphical 
presentations.
data collection and data management
Data collection, data assessment and data analysis will 
be performed according to the local guidelines for 
data management of the Erasmus MC Cancer Institute 
and Catharina Cancer Institute. All patient data will be 
collected in a central database according to the Euro-
pean law; General Data Protection Regulation (in Dutch; 
Algemene verordening gegevensbescherming) to protect 
confidentiality. Data collection and management will also 
be monitored on correctness by an independent trained 
monitor.
harms and auditing
All AEs, serious adverse events (SAEs) or suspected 
unexpected serious adverse reactions (SUSARs) will be 
recorded. All (S)AEs and SUSARs as a consequence of 
the administration of intraperitoneal irinotecan will be 
reported through the web portal ToetsingOnline to the 
accredited METC that approved the protocol, within 7 
days of first knowledge for (S)AEs and SUSARs that result 
in death or are life threatening followed by a period of 
maximum of 8 days to complete the initial preliminary 
report. All other (S)AEs and SUSARs will be reported 
within a period of maximum 15 days after the sponsor has 
first knowledge of the SAEs. In addition to the reporting 
of AEs, SAEs and SUSARs, the sponsor will submit, once 
a year throughout the clinical trial, a safety report to the 
accredited METC. The sponsor (Erasmus MC Cancer 
Institute, the Netherlands) is insured to provide cover for 
any patients who suffer harm from study participation.
Since this is a phase I ‘3+3’ dose- escalation study, all 
(S)AEs and SUSARs will be evaluated by the study team 
before the decision will be made to continue with the next 
dose- level. Therefore, no data safety monitoring board 
will be installed. The study is audited by an independent, 
qualified monitor according to the local guidelines of the 
participating hospitals.
Patient and public involvement
The Dutch patient association for patients with cancer in 
the digestive tract (Stichting voor Patiënten met Kanker 
aan het Spijsverteringskanaal, ‘SPKS’ In Dutch) and 
the Erasmus MC Cancer Institute work together closely. 
The patient association has received a copy of the study 
protocol and also received the patient information 
folder. Feedback on these documents was provided and 
the study was discussed during a brainstorm meeting at 
‘SKPS’ headquarters in Amersfoort, the Netherlands. The 
results of the study will be communicated to the patient 
association which van then distribute them among their 
members.
EThICS And dISSEMInATIon
Ethics approval and consent to participate
This study is approved by a research medical ethics 
committee (METC, Rotterdam, Netherlands, MEC-2018-
059) and the Dutch Competent Authority (CCMO, The 
Hague, Netherlands, EudraCT/NL2018-000479-33).
Written informed consent will be obtained from all 
patients participating in this study. The study will be 
conducted in compliance with the ‘Medical Research 
Involving Human Subjects Act’ (WMO) and according to 
the principles of the Declaration of Helsinki (64th World 
Medical Association General Assembly, Fortaleza, Brazil, 
October 2013).
Protocol amendments
Important protocol modifications are communicated to 
all investigators, the research METC, the Dutch compe-
tent authority (CCMO), and trial registries. The new 
protocol has to be approved by the METC and the CCMO, 
before it can be implemented.
dissemination
To generate more awareness and to increase referrals of 
potential study candidates, a short Dutch summary of the 
study will be published in The Dutch Journal for Oncology 
(NTVO in Dutch). Also, the study has been presented at 
the Dutch Society of Surgery meeting 2019 and at the 38th 
Congress of the European Society of Surgical Oncology 
in Budapest, Hungary. The results of this clinical trial will 
be submitted for publication in a peer- reviewed scientific 
journal.
dISCuSSIon
In this phase I, dose- escalation study patients are treated 
with concomitant intraperitoneal and systemic cytotoxic 
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therapy. The main goal of this study is to establish the 
MTD and RP2D of intraperitoneal irinotecan added to 
systemic FOLFOX and bevacizumab. Secondary goals are 
to explore the safety and feasibility of this treatment and 
to establish the pharmacokinetic profile of intraperitone-
ally administered irinotecan.
Previous research showed that the conversion of irino-
tecan to its active metabolite SN-38 takes place in the liver, 
but also occurs in the intraperitoneal cavity. However, 
little details are known about the process of the intra-
peritoneal conversion, and the amount, of irinotecan 
to SN-38. Therefore, establishing the pharmacokinetic 
profile of intraperitoneally administrated irinotecan is 
an essential part of this study, because this will provide 
crucial information for further research on the behaviour 
and use of intraperitoneally administrated irinotecan.
During this study we will also collect, process, and store 
ascites for translational research purposes. By systemati-
cally collecting ascites and isolating CTCs prior to each 
treatment cycle the opportunity is given to us to follow 
tumour heterogeneity and chemotherapy resistance. 
Furthermore, we will establish organoid cultures from 
ascites- derived CTCs as an ex vivo platform for studying 
drug response in individual patients. Gaining a deeper 
understanding into chemo- resistance will possibly allow 
us to determine which patients will respond best to which 
chemotherapeutic agent, and to which treatment they 
are resistant. This could be valuable information for both 
the palliative treatment with chemotherapy, as well as for 
the curative approach, for example, patients who are still 
eligible for CRS- HIPEC.
To the best of our knowledge, this is the first study in 
patients with peritoneal metastases of colorectal origin 
that combines standard of care systemic chemotherapy 
with intraperitoneal chemotherapy. This study will give 
us essential information, the MTD/RP2D, safety and 
feasibility of treatment with intraperitoneal irinotecan, 
for the conduction of further clinical research. A phase 
II clinical trial is already being designed to follow this 
phase I trial, which will shed more light on actual effects 
of the addition of intraperitoneal irinotecan to systemic 
FOLFOX and bevacizumab on the oncological outcomes 
and survival rates of these patients. The INTERACT 
study may be the first step towards a more effective, life 
prolonging and possible even curative treatment for this 
specific patient group.
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